All Activity

A combination of the marijuana components THC and CBD leads to a significant and sustained reduction in agitation in the vast majority of people with Alzheimer’s disease of other forms of dementia, according to a new federally funded study. The placebo-controlled, double-blind trial involved a cannabis preparation called T2:C100 that contained 2mg THC and 100mg CBD, and included 120 people with dementia who were eligible to receive hospice care and were experiencing clinically significant agitation. The researchers, from Medical University of South Carolina and Georgetown University, found that there was a “statistically significant improvement” in scores on a standardized scale to systematically assess agitation among patients who received the cannabis medication as compared to the placebo group—measured at both two weeks into the trial and at the end of the full 12-week study. After week two, 84 percent of participants receiving THC and CBD improved, according to the caregiver-rated scale, compared to 31 percent of those who got the placebo. After the full trial, 87 percent of those who got the cannabis medication manufactured by MediPharm Labs saw improvement, as compared to 24 percent in the placebo group. The results, presented at the Alzheimer’s Association International Conference this month, suggest that the “THC/CBD combination used in the study may be an important therapeutic tool” for patients with agitation and Alzheimer’s disease or other types of dementia, according to the abstract. “This is a robustly positive, randomized, controlled trial that represents a major step forward in treatment for a population that has been historically overlooked in clinical research,” lead investigator Jacobo Mintzer said in a press release. “We now have evidence supporting a new and very effective treatment approach for agitation that may be appropriate for people in the final stages of dementia at the end of life, offering them grace and peace in what is often an extremely difficult time for patients and their families.” “These trial results were extremely impressive and showed a level of response not seen before in clinical trials related to dementia,” he said. “Rarely do we see close to 90 percent of patients in a trial respond positively to a new medication.” The Life’s End Benefits of cannaBidiol and tetrahYdrocannabinol (LIBBY) study, which involved patients with an average age of 80.5 years, was funded by the National Institutes of Health and the Alzheimer’s Association. “The LiBBY study directly addresses one of the most challenging and under-discussed aspects of Alzheimer’s disease—end-of-life agitation,” Elizabeth Edgerly, voce president for care and support for the Alzheimer’s Association, said. “These results not only highlight a promising therapeutic option, but also underscore the importance of prioritizing attention, care and research for individuals in mid- and late-stage Alzheimer’s and related dementias.” Brigid Reynolds, a co-principal investigator on the study, said that “proving the clear benefit of THC/CBD over placebo can bring hope to millions of patients, their families, caregivers and loved ones.” “Agitation affects many people with late-stage dementia, causing symptoms such as restlessness, aggression and emotional distress that can profoundly impact patients and their caregivers,” she said. “Current treatment options are limited and often carry significant side effects, underscoring the need for safer, more effective therapies.” Meanwhile, the American Medical Association adopted a resolution last month recognizing both the risks and potential therapeutic benefits of marijuana use by older adults. It simultaneously notes that there is a “higher incidence of dementia among individuals who use cannabis” but also that “cannabis may offer therapeutic benefits for managing agitation in dementia patients, potentially serving as an alternative to antipsychotic medications.” A study published last year found that CBD shows “promising” results to reduce inflammation and cognitive decline associated with aging. In 2024, a scientific review concluded that THC, CBD and lesser-known phytocannabinoids, terpenes and flavonoids in marijuana are “promising agents in treating neurodegenerative disorders.” The post THC And CBD From Marijuana Reduces Agitation In 9 Out Of 10 People With Alzheimer’s Or Other Dementia, Study Shows appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Officials in Alabama have scheduled a public hearing for this week to receive input on whether the state should reclassify marijuana in conjunction with the Trump administration’s move to federally reschedule cannabis. Under state law, federal rescheduling of a drug automatically triggers state-level reclassification within 30 days unless Alabama officials proactively object. “In that case, the State Board of Health shall publish the reasons for objection and afford all interested parties an opportunity to be heard,” state statute says. “At the conclusion of the hearing, the State Board of Health shall publish its decision, which shall be final unless altered by statute. Upon publication of objection to inclusion, rescheduling, or deletion under this chapter by the State Board of Health, control under this chapter is stayed until the State Board of Health publishes its decision.” The Alabama State Committee of Public Health in May issued a preliminary objection to cannabis rescheduling, with members saying they needed more time to determine how to implement such a reform in light of the state’s recently launched medical cannabis market. Scott Harris, the state health officer, said at the time that Alabama “fully intends” to follow the federal change. “We’re not saying Alabama’s not going to do this,” he said. “We certainly are going to do this, but if you receive it without objection, it’s scheduled immediately. If you do nothing, it’s scheduled within 30 days. I’m going to ask you to take the third option, which is to object. Then we just have a little bit of time to figure this out with all of our other stakeholders.” Now, Harris said in a new notice that the committee will hold a public hearing on Wednesday, July 22, to further weigh the issue. “Following input from the various Alabama governmental entities which could be affected by the rescheduling and from those people who provide testimony at the public hearing, the Committee will reconsider whether to continue its objection or whether to adopt the rescheduling,” he wrote. Under an order issued by U.S. Acting Attorney General Todd Blanche in April, marijuana products regulated by a state medical cannabis license immediately moved from Schedule I of the Controlled Substances Act (CSA) to Schedule III, as did any marijuana products that are approved by the Food and Drug Administration (FDA). An administrative hearing is considering broader marijuana rescheduling. “In light of Alabama’s substantial work to establish its own framework for the dispensing of medical marijuana, additional time is needed to evaluate whether the federal rescheduling will alter that framework as outlined by the Legislature,” Harris’s notice says. “A public hearing on this matter will provide [the Alabama Department of Public Health] the opportunity to hear from the citizens of Alabama as well as stakeholders regarding this decision. The Committee wishes to make a reasoned, considered decision on this issue with input from all appropriate persons.” Aside from the public hearing, people can submit written comments on the issue through August 5. Alabama is not the only state considering whether and how to follow the federal government’s marijuana rescheduling move. A GOP senator in South Carolina, for example, said that “medical marijuana is now legal” in the state under a trigger law. Wyoming’s attorney general determined this month the state will not reclassify marijuana despite the Trump administration’s federal reform. Tennessee Gov. Bill Lee (R), meanwhile, signed legislation this session to block an automatic review that could have potentially legalized medical marijuana under state law following the federal rescheduling of the drug. Photo courtesy of Mike Latimer. The post Alabama Officials Will Hold Hearing On Whether To Reschedule Marijuana In Line With Trump’s Federal Move appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

My partner and i astonished with all the examination an individual built to get this distinct distribute extraordinary. Great action! slot gacor

Marijuana consumers’ support for the Trump administration’s actions on cannabis has declined in the months since the Department of Justice first announced it was moving forward with rescheduling the drug, a new survey reveals. The latest quarterly presidential approval tracking poll from NuggMD and Marijuana Moment shows that 48 percent percent of marijuana consumers now either “approve” or “strongly approve” of the Trump administration’s cannabis actions. A total of 13 percent disapprove, and 40 percent say they have no opinion or are neutral. The numbers represent a significant drop in cannabis’ consumers support for the Trump administration’s actions on the issue from last quarter, when favorability came in at 73 percent. “Do you approve or disapprove of the presidential administration’s actions on cannabis?” n: % Strongly approve 76 15% Approve 166 33% No opinion/Neutral 202 40% Disapprove 43 8% Strongly disapprove 23 5% Acting Attorney General Todd Blanche in April issued an order that immediately reclassified state-licensed medical cannabis, as well as marijuana products approved by the Food and Drug Administration (FDA) from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Under a separate order the acting attorney general signed, a hearing is considering more comprehensively moving marijuana to Schedule III. Testimony in the cannabis rescheduling hearing, overseen by a Drug Enforcement Administration (DEA) judge, concluded last week, and participants are now set to file their final briefs by August 17. After that, the judge will issue his own recommendation on rescheduling, and the DEA administrator will then issue a final decision on whether or not to adopt the reform. A separate recent NuggMD poll conducted this month found that most cannabis consumers aren’t optimistic that marijuana rescheduling will be fully implemented by the end of the year. “Rescheduling continues to be popular among cannabis voters, but our polling shows a clear divide between support for medical rescheduling versus recreational reforms,” Tyler Elson, NuggMD’s director of content, told Marijuana Moment. “That or we’re seeing consumers declare that they don’t believe the DEA will get rescheduling done.” “I’m not surprised that support among consumers is down from the highs we saw after medical cannabis rescheduling. There have always been cannabis voters who draw a line between medical and recreational use,” he said. “I think the White House was expecting the formal rescheduling hearing to maintain that momentum among cannabis voters. And right now that’s not what our polling is showing.” When asked in the latest poll how their support for the administration would change if it were to more fully legalize marijuana, 54 percent of cannabis consumers said they would either support it much more (39 percent) or a bit more (15 percent), and 46 percent said their level of support would not change. “If the Trump administration were to more fully legalize cannabis, would that change your level of support for it?” n: % I would support it much more 198 39% I would support it a bit more 78 15% No change 233 46% I would support it a bit less 0 0% I would support it much less 1 0% The new survey involved interviews with 510 cannabis consumers who live in states with legal markets from July 9-15, with a +/-4.34 percentage point margin of error. Meanwhile, DEA, which has been charged with defending the rescheduling proposal during the hearing has focused testimony on the medical benefits of cannabis and its relative safety compared to alcohol and other substances—despite excluding reform supporters from participating in the proceedings. The cannabis rescheduling move is also being challenged in court through a number of lawsuits from the drug testing industry, a pharmaceutical corporation, legalization opponents and others. The results of the prior quarterly NuggMD/Marijuana Moment tracking poll represented a massive swing in support for the Trump administration’s marijuana policy actions from consumers compared to the last quarter of 2025, before the president issued an executive order directing officials to finalize rescheduling. White House Press Secretary Karoline Leavitt said in April that the administration is moving forward with marijuana rescheduling because cannabis reform is “overwhelmingly popular” with voters and because doing so will help people who need access to the drug for medical purposes. In May, a House committee voted to block federal officials from taking further steps to carry out cannabis rescheduling. The post Marijuana Consumers’ Support For Trump’s Actions Drops As Most Don’t Believe Rescheduling Will Be Completed This Year, Poll Shows appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Those photos from the Back to the 90's event captured such a fun vibe, and it's cool that Ladies of Paradise sent them over. Looking at these shots, I feel like turning some of them into cartoon-style portraits withAI Cartoon Generator would be a creative way to keep the throwback energy going.

Next steps in DEA marijuana hearing; Rescheduling lawsuit filing; Study: Music & cannabis; State hemp developments in OH, FL & MO Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Hold on, just one second before you read today’s news. Have you thought about giving some financial support to Marijuana Moment? If so, today would be a great day to contribute. We’re planning our reporting for the coming months and it would really help to know what kind of support we can count on. Check us out on Patreon and sign up to give $25/month today: https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW A multi-day Drug Enforcement Administration hearing on the Trump administration’s marijuana rescheduling proposal concluded, with an agency judge issuing an order that lays out next steps and the schedule for participants to file post-hearing briefs. New Federal Election Commission records show that several of the U.S.’s largest marijuana companies donated a collective $11.5 million last month to an agriculture-focused political committee that shares the same treasurer as President Donald Trump’s own super PAC. The drug testing industry and a pharmaceutical corporation are asking a federal court to block the Trump administration’s cannabis rescheduling move—claiming it will “increase marijuana abuse” and dismissing the government’s criticism that they have “pocketbook interests” in opposing the reform. A new government-funded study found that combining music and marijuana “typically helps reduce fear and anger while enhancing feelings of happiness, liveliness, relaxation, and nostalgia.” “Participants frequently reported the use of cannabis as a substitute for pharmaceutical treatments for pain, anxiety, and sleep disorders, with music further amplifying these therapeutic effects.” A federal judge placed a preliminary injunction on enforcement of Ohio’s hemp THC product restrictions against 10 specific companies while litigation challenging the policy proceeds. Missouri officials are facing a federal lawsuit over a ban on hemp THC products that is set to take effect later this year. Florida hemp businesses are concerned about the impact of the scheduled federal recriminalization of hemp THC products later this year—though some industry operatives are hopeful the Trump administration can convince Congress to reverse course. Several states advanced legislation this year to let first responders use medical cannabis or psychedelics to treat PTSD. / FEDERAL White House Office of National Drug Control Policy Director Sara Carter said it would be a “disaster” to end the war on drugs, arguing it would be “the beginning of the end of the American people.” The Food and Drug Administration tweeted, “FDA’s new guidance and MOU with @DeptVetAffairs on psychedelic drug development could open new doors for veterans battling PTSD. By supporting rigorous clinical research into psychedelic therapies, we’re helping advance potentially transformative treatment options for those who’ve served our country.” Rep. Haley Stevens (D-MI), who is running for U.S. Senate, spoke about her support for legalizing marijuana. / STATES Kansas gubernatorial candidates discussed their views on marijuana policy. The Pennsylvania House Majority Policy Committee posted a tweet pushing Senate Republicans to take up marijuana legalization legislation. A California judge tentatively ruled that recently enacted changes to how marijuana revenue is allocated are constitutional. Colorado regulators are proposing changes to marijuana rules. A new member of the New Jersey Cannabis Regulatory Commission was appointed. Michigan regulators entered into consent orders with a marijuana business under which it will surrender its license and cease operations over alleged violations. Oregon regulators extended the deadline to apply to serve on a rules advisory committee about marijuana testing. The Virginia Cannabis Control Authority Board of Directors will meet on Wednesday. The Guam Cannabis Control Board will meet on Wednesday. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / LOCAL The Kalamazoo, Michigan City Commission will consider changes to the city’s marijuana social equity policies on Monday. / INTERNATIONAL German officials have approved four marijuana research projects. / SCIENCE & HEALTH A review concluded that “CBD reduces anxiety-like and depressive-like behaviors and improves cognitive performance across a variety of preclinical models.” A review concluded that “psychedelics have significant potential in [treatment-resistant depression] with superior mechanisms over traditional antidepressants. / ADVOCACY, OPINION & ANALYSIS The New York Post editorial board said it may be time for officials to begin “rethinking legalization altogether.” / BUSINESS The Securities and Exchange Commission won a judgement against American Patriot Brands, Inc. and its executives and subsidiaries over fraud charges. Green Thumb Industries workers in New Jersey voted to remove United Food and Commercial Workers Local 360 union officials from their workplace. Arkansas dispensaries sold $140.3 million worth of medical cannabis products in the first six months of the year. / CULTURE Seth Rogen discussed his role in helping to normalize marijuana use through his work. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: The post Cannabis companies make big donations to Trump-linked PAC (Newsletter: July 20, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

I wanted to thank you for this excellent read!! I definitely loved every little bit of it. I have you bookmarked your site to check out the new stuff you post. แทงบอล

I just found this blog and have high hopes for it to continue. Keep up the great work, its hard to find good ones. I have added to my favorites. Thank You. แทงบอล

“When you are in the fire service, or any first responder industry, or especially in the military, stuff builds up over time, and what happens is you see so many things that the crazy stuff starts to at least seem normal.” By Amanda Watford, Stateline More states this year have looked beyond traditional counseling and medication to help first responders cope with post-traumatic stress. Firefighters, police officers and emergency medical workers routinely witness fatal crashes, violent crimes and other traumatic events that can leave lasting psychological scars. “When you are in the fire service, or any first responder industry, or especially in the military, stuff builds up over time, and what happens is you see so many things that the crazy stuff starts to at least seem normal,” said Jason Cerrano, a retired firefighter and paramedic with more than 20 years of experience in Missouri. Cerrano is now the director of commercial research and development at IDEX Fire & Safety. In Ohio, Republican Gov. Mike DeWine last month signed into law a measure that will create a Post-Traumatic Stress Injury Commission to review applications from eligible first responders for assistance to help cover treatment costs. Maryland took a different approach this year, enacting a law that protects firefighters, emergency medical technicians, paramedics and other rescue workers from employment discrimination over the lawful off-duty use of medical marijuana. The new law, which goes into effect in October, applies to registered medical cannabis patients who test positive for cannabis metabolites but are not impaired while on duty. Several other states are exploring emerging therapies. A new Connecticut law expands a pilot program at Yale University studying psilocybin-assisted therapy by allowing any state resident age 18 or older to participate, provided they meet the clinical eligibility criteria established by Yale University’s institutional review board. The pilot program was previously limited to veterans, retired first responders and frontline health care workers. Missouri lawmakers advanced a bill allowing veterans and first responders in approved research studies to receive the psychedelics psilocybin and ibogaine under medical supervision for PTSD and other mental health conditions. The legislature adjourned in May before lawmakers could send the bill to the governor. This story was first published by Stateline. Image element courtesy of Kristie Gianopulos. The post States Move To Let First Responders Use Marijuana And Psychedelics To Treat PTSD appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Hey, this day is too much good for me, since this time I am reading this enormous informative article here at my home. Thanks a lot for massive hard work. แทงบอลออนไลน์

“The category’s too big to fail. The consumer demand is there. The infrastructure is in place. I don’t think that it’s going anywhere. It’s a matter of when and how we get regulated.” By Mitch Perry, Florida Phoenix On Saturday, St. Petersburg retailer Herban Flow hosted its third High and Dry Festival, which featured dozens of brands showcasing THC-infused drinks, plus adaptogens, nootropics and alcohol-free libations. Herban Flow owner Michael Smith says that about 80 percent of sales from his two stores come from hemp-derived THC products, which is why he’s anxious about an impending federal ban on virtually all intoxicating and non-intoxicating hemp and CBD products, effective November 12. “It’s amazing how many people still don’t know about it,” Smith said. “So many people are now just discovering it and they don’t believe me when I tell them in three months that all of this is going away.” That possibility began to emerge last November, when Congress passed a spending bill which included a change to the federal definition of legal hemp to a “total THC standard” rather than Delta-9 THC only. Final-form hemp-derived products would be capped at 0.4 mg total THC per container. Translated, that would render approximately 95 percent of existing hemp-derived products federally illegal, according to the U.S. Hemp Roundtable. Florida hemp entrepreneurs say the pending ban is already harming their commerce. “Farmers are not putting plants in this season because if they harvest them in September or October, and then they find that the product becomes illegal in November, that’s a problem,” said Jammie Treadwell, CEO of Treadwell Farms in Umatilla. “So, I’m getting questions: Should I renew my license? Should I put plants in? Usually, by this time we’ve sold [products] to about 20 farmers. So far this year, we’ve sold to about six and for the ones who have purchased, they’ve purchased less than in prior years. So it’s already impacting me.’” Although it’s been reported that the pending ban threatens to remove just intoxicating and synthetic cannabinoid products, industry officials say it would also remove full-spectrum non-intoxicating CBD products used as alternatives to over-the-counter painkillers or prescription medications. The White House weighs in President Donald Trump wants Congress to overturn the ban, at least as it relates to hemp-derived CBD. “I am calling on Congress to update the Law to ensure that Americans can continue to access the full-spectrum CBD products they have come to rely on, and that help them, while preserving Congress’s intent to restrict the sale of products that pose Health risks,” Trump posted on his Truth Social page on April 23. “We must get this done RIGHT and FAST, especially for those who saw that CBD helps them. Plus, I am told it will also help our GREAT FARMERS, who we love, and will always be there for. Please get it done, and SOON.” David Shiffman is CEO of Amigos, a South Florida hemp-derived THC brand, as well as Tillman Tranquils, which offers edibles, gummies and mints. He’s played by the rules since hemp became legalized in Florida in 2019, he said—he’s paid his fees, passed state inspections, made improvements and updated packaging materials per the regulations the Legislature approved in recent years. “Trying to build a business by the book and then having the rug pulled out by new legislation is a scary thing for any business, especially a small business here in Florida for us and for our employees,” he said. Shiffman is confident that because of the directives coming out of the White House, a permanent ban isn’t likely to happen. “I hate to say it, but the category’s too big to fail,” he said. “The consumer demand is there. The infrastructure is in place. I don’t think that it’s going anywhere. It’s a matter of when and how we get regulated.” Jammie Treadwell’s family has had roots in Florida agriculture for more than a century and still grows citrus, peaches and blueberries. The family made a hard pivot to hemp after it was legalized in the state, launching Treadwell Farms in 2019. Hemp is a “perfect plant” for Florida because it can be grown year-round and allowed the family to take its agriculture legacy into the next generation, she said. But agriculture is a tough business and, after surviving hurricanes and the deepest freeze in 16 years in January, she said, farmers are watching their pocketbooks more than ever. “I don’t want to sound dramatic, but it could very well put us out of business,” she said of the pending ban. “Our business has grown every year, but we’re still a small business and there’s only so many hits that you can take. And so, for us to reformulate everything and potentially lose some of the products that are good sellers? I mean, it’s a daunting thing.” Russell Vought, director of the Office of Management and Budget, sent a letter to House Speaker Mike Johnson on June 24, calling on Congress to revise the federal regulation of hemp “to ensure the fair treatment of hemp products,” similar to an amendment filed by Kentucky House Republican Andy Barr called the “Lawful Hemp Protection Act,” which would overhaul the pending hemp restrictions with a taxed and regulated framework. That legislation includes establishment of a three-tier distribution system for hemp-derived beverages, modeled on the distribution system used for alcohol—something Smith with Herbal Flow doesn’t want any part of. “It’s pushing into alcohol regulation,” he said. “Their whole claim is that it’s an intoxicating beverage so it should be treated like that but, at the end of the day, they don’t have child-resistant tops on Bacardi 151,” he said. “They’re able to put out Hard Mountain Dew and SunnyD without any label restrictions in that sense,” he added. “So, they’re not really treating us like alcohol, but they want to treat us as alcohol.” If the federal ban were lifted or delayed, it would open another lifeline to Florida hemp entrepreneurs who have dodged potential existential threats to their livelihoods in recent years. States have already banned or restricted intoxicating hemp The Legislature approved a proposal to restrict intoxicating hemp products and sent it to Gov. Ron DeSantis (R) two years ago, which he vetoed. In his message, DeSantis said the bill would have imposed “debilitating regulatory burdens on small businesses” and done “dramatic disruption and harm” to retail businesses. After that close call, Florida House Speaker Daniel Perez (R) announced just ahead of the 2025 legislative session that he was creating a “combined workgroup” on hemp. Although not tasked with producing any specific policies, the workgroup concluded its meetings by saying that although members didn’t want changes that could destroy the industry, the status quo had to change in terms of hemp’s regulatory framework. Ultimately, key differences between the Senate and House bills prevented any legislation making it way back to DeSantis that year. Contrast that with the fact that hemp-based intoxicants are already illegal or heavily regulated in more than a dozen states. The Florida Department of Agriculture and Consumer Services oversees the hemp industry in Florida. The Phoenix reached out to the office to ask where Commissioner Wilton Simpson stands on the impending ban, but his office did not respond to two attempts for comment. This story was first published by Florida Phoenix. The post Florida Hemp Businesses Hope Trump Can Save Them From Planned Federal Ban On THC Products appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

You will be permitted to posting companies, yet not one-way links, except in cases where they can be permitted plus for issue. situs togel

For a Amateur, We're entirely studying internet to get reports that is with help people. Thanks a ton. Royal X Casino Game

This is the details My business is locating everywhere you go. Appreciate it on your blog site, I just now signed up your site. That is a pleasant blog site. inch. Bola88

It is trendy write-up in addition to i love to to learn to read that write-up. your site is usually excellent therefore you include beneficial workers with your blog site. pleasant giving thanks. bandar togel

Are you looking for a fast-paced, skill-demanding, and completely free game to unwind? Snow Rider 3D is the perfect answer. With its vivid three-dimensional graphics and thrilling gameplay, this online skiing game is currently dominating the charts. In this article, we will dive into the ultimate tips and tricks to help you smash high scores and unlock all the coolest sleighs!

“This isn’t consumer protection. It’s the elimination of an entire legal industry coupled with a government-mandated monopoly.” By Rebecca Rivas, Missouri Independent A coalition of hemp businesses filed a federal lawsuit Thursday in an attempt to halt a statewide ban on intoxicating hemp products from going into effect in November. The lawsuit, filed in the U.S. District Court for the Western District, claims the ban state lawmakers passed this spring contains “unconstitutionally vague” definitions for hemp and marijuana. Craig Katz, government relations and compliance manager for one of the plaintiffs, St. Louis-based MNG 2005, Inc., said the problem begins with lawmakers’ lack of understanding about the cannabis industry. “A lot of this stuff is kind of in the weeds,” Katz said. “It’s very difficult to understand. And when people are trying to legislate it, if they don’t understand it, you come up with something like HB2641, which doesn’t make a whole heck of a lot of sense.” The coalition includes MNG, which is the parent company for 55 CBD Kratom stores nationwide, the Missouri Hemp Trade Association and a Wisconsin-based hemp business, Lifted Liquids Inc. The bill in question was among the first Missouri Gov. Mike Kehoe (R) signed this year and will take all intoxicating hemp products off the shelves starting November 12—including THC seltzers currently sold in bars and grocery stores. The legislation largely aligns state law with the upcoming federal ban that Congress approved last year. Under Missouri’s bill, if Congress reverses course and decides to allow the sale of these products, the state would only permit them in licensed marijuana dispensaries. And if Congress delays the ban for a couple years, Missouri law would still ban all products, except for intoxicating beverages. It also tasks Missouri Attorney General Catherine Hanaway (R) with enforcement. Kehoe, Hanaway and Sarah Wilson, director of the Missouri Department of Health and Senior Services which oversees the state’s marijuana program, are the named defendants. Hanaway’s spokeswoman said the office had not been served the lawsuit. Kehoe’s office and DHSS declined to comment since it’s pending litigation. Similar bills have been debated since 2023, but failed to pass. Without regulations, intoxicating hemp products with as much as 1,000 mg of THC are currently sold in smoke shops—outside of Missouri’s licensed marijuana dispensaries. The bill’s sponsor, Rep. Dave Hinman, a Republican from O’Fallon, said the legislation largely gives state law enforcement and prosecutors the authority to enforce the federal hemp ban after November 12. “ I believe this is the last ditch effort for the hemp industry,” Hinman said. “HB2641 passed the Missouri House, Senate and was signed by the governor. It was vetted throughout the entire process. I don’t believe this Hail Mary will get the results the Hemp Trade Association wants, and Missouri will mirror the federal government.” The lawsuit argues that the bill defines the same products as both “hemp” and “marijuana” in different provisions, which leaves businesses, law enforcement and prosecutors confused about what is legal. “Because unlicensed marijuana activity is a crime in Missouri, that confusion carries criminal consequences,” states the coalition’s press release announcing the lawsuit. While the bill “promises” not to interfere with interstate hemp commerce, the coalition notes that it also restricts who may transport hemp products through the state, the press release states. And it contains effective date provisions “so convoluted that businesses cannot determine which products are covered or when,” it said. The coalition believes the “confusing” definitions will also take non-intoxicating CBD products off Missouri shelves. “This isn’t consumer protection,” said Jay Patel, the association’s president. “It’s the elimination of an entire legal industry coupled with a government-mandated monopoly.” This story was first published by Missouri Independent. The post Missouri Hemp THC Product Ban Challenged With Federal Lawsuit Filed By Industry appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

“While this case involves hemp products, it is really a win for businesses and consumers across America.” By Phillip Smith, The American Hemp Monitor A federal district court judge in Toledo ruled Monday that state officials are barred from enforcing the state’s ban on hemp-derived intoxicating cannabinoids in beverages, but only the 10 companies that filed a lawsuit against the rules and vendors who sell their products are protected from enforcement. The legislature last year passed Senate Bill 56, which tightened the state’s voter-approved recreational marijuana law, but also included provisions defining most intoxicating hemp products as cannabis and barring companies outside the state from growing or selling hemp products. A handful of hemp companies filed suit against the state, challenging the constitutionality of the new law. U.S. District Judge Jeffrey Helmick had earlier approved a temporary restraining order barring the state from moving against those companies, and on Monday, finding the plaintiffs’ arguments compelling, he issued the preliminary injunction to last while the case is argued. “What Senate Bill 56 has done is to exclude federally legal intoxicating hemp products from Ohio’s statutory definition of hemp, redefine them as illegal marijuana, and then to prohibit any company from cultivating or selling those products unless the company has a physical presence in the state of Ohio,” Helmick wrote. “Because plaintiffs are likely to succeed on their claim that that law impermissibly favors in-state companies over out-of-state companies in violation of the Constitution of the United States, I grant plaintiffs’ motion for a preliminary injunction,” the judge wrote. The state provided no evidence that federal law expressly allowed states to favor in-state companies, Judge Helmick said. He also pointed to Supreme Court precedent holding that states cannot discriminate against interstate commerce when there are reasonable non-discriminatory alternatives. “None of the defendants have rebutted plaintiffs’ assertion during the temporary restraining order hearing that the legislature considered implementing age minimums and potency testing for all intoxicating hemp products made available for sale in Ohio, and no defendant has explained why these non-discriminatory alternatives are inadequate to satisfy Ohio’s legitimate public health and safety concerns without discriminating against out-of-state companies,” the judge wrote. Hemp company attorney Andy Mayle pronounced himself pleased with the ruling, which he called an “efficient and forceful explanation of how the state violated the federal Constitution” in approving Senate Bill 56. “While this case involves hemp products, it is really a win for businesses and consumers across America because it explains how the federal Constitution prevents all states from banning products just because the products were manufactured in another state,” Mayle said. “Just as our clients’ hemp products are protected from being discriminated against in Ohio, Heinz Tomato Ketchup made in Fremont or Whirlpool washing machines made in Clyde and Findlay cannot be banned from being exported to other states,” he continued. “This experience adds a little belated zest to our clients’ America 250 celebrations.” Julie Pfeiffer, Ohio assistant attorney general and lead counsel in the case, had argued that since Congress had passed legislation regulating hemp (which will not go into effect until November), the Commerce Clause was not implicated. She also argued that allowing the hemp beverages to be sold would expose Ohioans to dangerous unregulated products, but she could not cite any poisonings back to the plaintiffs. Judge Helmick didn’t buy those arguments. The state can try to make them again as it defends itself against the lawsuit later. This story was first published by The American Hemp Monitor. The post Federal Judge Blocks Enforcement Of Hemp THC Product Ban Against Ohio Companies appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

A beats might be fantastic. You possess numerous especially capable actors. I just aspire most people the right from victory. slot

My partner and i astonished with all the examination an individual built to get this distinct distribute extraordinary. Great action! alexistogel

Discount put up, Regards for the purpose of showing This unique practical knowledge. Excellently crafted piece of writing, if perhaps virtually all web guru proposed an identical standard of articles and other content whenever you, the on-line world will be more effective destination. Why not keep writing! situs slot

We know just how to satisfy your wishes because we have years of experience in the field. Our Russian Escort Dwarka provide the ideal balance of fun, attractiveness, and professionalism, whether you require a companion for a business function, a night out in Dwarka, or some alone time in your hotel.

This whole vibe sounds so fun—like stepping into a creative, laid-back space where you can talk and just be yourself. I really love meeting new people and having random conversations, and it reminds me of Omegle in the best way. You never know who you’ll connect with, and somehow those moments make the experience feel more human and relaxed.

A drug testing industry association and a pharmaceutical company are asking a federal court to block the Trump administration from moving forward with federal cannabis rescheduling while ongoing litigation challenging the reform is considered—arguing that “marijuana abuse has dangerous, lifelong consequences—especially for adolescents and pregnant women.” The new filing claims that “by cutting taxes on cannabis companies,” federal rescheduling “will stimulate the industry and increase marijuana abuse.” The brief, filed on Thursday, comes in response to the Department of Justice’s opposition to the drug testing group and pharma company’s motion to pause the rescheduling move. The government, in its brief earlier this month, noted that the entities challenging cannabis rescheduling have “pocketbook interests served by keeping all marijuana in schedule I” and are not suitable challengers to the reform because they are not the “intended beneficiaries” of the Controlled Substances Act (CSA). The filing this week from opponents, however, claims that DOJ’s arguments on standing are “meritless diversions from its indefensible position on the merits.” “Movants need not be ‘intended beneficiaries of the CSA,'” it says. “Nor does it matter that movants have ‘pocketbook interests’ at stake while the CSA has broader objectives aimed at the general welfare. ” The U.S. Court of Appeals for the District of Columbia is currently weighing three separate lawsuits against moving cannabis from Schedule I of the CSA to Schedule III that have since been consolidated. One suit is led by prohibitionist organization Smart Approaches to Marijuana (SAM) and the National Drug and Alcohol Screening Association (NDASA), who claim they are “aggrieved” by the reform. Another comes from a coalition of anti-marijuana activists, substance misuse professionals, doctors and a cannabis-focused biopharmaceutical corporation. A third challenge was filed by the attorneys general of Indiana, Nebraska and Louisiana—though the latter state later withdrew from the suit. Two of the entities involved in the litigation—NDASA and MMJ International Holdings and its subsidiaries—filed a separate motion asking the court to place a stay on marijuana rescheduling while the broader challenge is considered. In the latest filing, their attorneys argue they would “suffer irreparable harm” from the federal cannabis reform. Expected new costs related to medical review officer (MRO) practices that will be imposed on NDASA members in the drug testing industry “will force some to go out of business,” it says. “Because the Order renders marijuana legal for state ‘medical’ use, MROs will need to perform time-intensive checks to determine whether positive THC tests are attributable to licit uses. That causes unrecoverable losses—irreparable harm—in two ways. First, NDASA’s MRO members will absorb some of the new costs themselves, incurring unrecoverable losses that cannot be dismissed as mere ‘voluntary billing decision[s].’ Second, whatever they do not absorb themselves will be passed on through higher prices, which will cause some clients to drop marijuana testing. It is not ‘speculative’ that some clients will drop more expensive testing; it is the inevitable result of the ‘commonsense economic realit[y]’—often relied on by courts—that demand falls as prices rise.” The brief also argues that rescheduling “compels the many NDASA members that require employee drug testing either to (1) drop marijuana testing and live with the substantial risk of impaired-employee accidents and diminished productivity, or (2) pay substantially more to test for marijuana and risk Americans With Disabilities Act (ADA) or state-law liability for acting on positive tests.” In response to the government’s argument that NDASA isn’t an appropriate entity to challenge rescheduling because it isn’t an intended beneficiary of the CSA, the brief says that the group’s members “translate CSA prohibitions into concrete practices that protect the public.” “Drug testing creates a deterrent that is essential to the CSA’s ‘main objective[] of combating drug abuse.’ Thus, NDASA members’ interests in marketing drug-testing devices and services—and their clients’ interests in safe, drug-free workplaces—are certainly ‘consistent with the purposes of the statute.'” Additionally, “NDASA’s members who test their employees have a strong interest in ensuring safety for both their employees and members of the public who may be affected by their work,” it says. “That interest is self-evidently congruent with the purposes of the CSA. Rescheduling marijuana harms that interest by necessitating costly revisions to drug-testing policies; by making marijuana testing itself more expensive; and by exposing NDASA members who act on positive marijuana test results to substantial risk of ADA and state-law liability.” MMJ, for its part, will also see harm to its “competitive position in the market for federally lawful cannabis-based pharmaceuticals,” the filing claims. “Until the Rescheduling Order, MMJ enjoyed a strong first-mover advantage because of its unbroken track record of federal compliance and significant progress toward an FDA-approved cannabis-based product. The Order destroys that competitive advantage—which reflects eight years of hard work and $10 million of investment—by making federally lawful the products of competitors who have long spurned federal law to capitalize on state medical marijuana programs.” “These harms cannot be dismissed on the theory that MMJ” has thus far failed to bring any cannabis drugs to market, as the government pointed out in its brief, the company’s attorneys wrote. “MMJ has jumped through countless hoops over eight years to seek DEA registration and FDA approval, while its competitors ‘have taken few steps’—indeed, no steps—toward seeking federal drug approval.” “MMJ has spent nearly eight years and $10 million to comply with federal law in developing a cannabis therapeutic,” the filing says. “The Rescheduling Order suddenly creates federally licit competition from state-legal cannabis drugmakers—which, to date, have made no effort to comply with federal drug laws.” NDASA and MMJ also argue that the overall litigation challenging rescheduling is likely to ultimately succeed on the merits, saying that the proposed rule is “unlawful” because the government failed to undergo formal rulemaking procedures in an “egregious violation” of federal statute. “The public interest plainly supports a stay,” it concludes. The latest filing in the legal dispute comes as a Drug Enforcement Administration (DEA) hearing on the marijuana rescheduling proposal concluded testimony and the judge overseeing the proceedings laid out next steps for filings that will lead to his own recommendation on whether the reform should be adopted. Acting Attorney General Todd Blanche in April issued an order that immediately reclassified state-licensed medical cannabis, as well as marijuana products approved by the Food and Drug Administration (FDA) from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Under a separate order the acting attorney general signed, the hearing is considering more comprehensively moving marijuana to Schedule III. Meanwhile, two medical marijuana companies filed a motion to intervene in the rescheduling lawsuit by joining the side of the government and opposing the litigation from prohibitionists. Lawyers for NDASA and SAM, however, filed a brief arguing that the cannabis businesses should not be allowed to join the suit. The suit from SAM and NDASA challenging rescheduling was signed by attorneys at Torridon Law PLCC, where former U.S. Attorney General William Barr, led DOJ during Trump’s first term in office, is a partner. SAM had announced in January that it was hiring Barr’s firm to legally combat cannabis rescheduling after Tump signed an executive order directing officials to complete the process expeditiously. Meanwhile, the House Appropriations Committee voted to block federal officials from taking further steps to carry out cannabis rescheduling. Bipartisan lawmakers told Marijuana Moment, however, that they don’t expect the legislative effort to block rescheduling to succeed. Separately, SAM, MMJ and other plaintiffs filed a lawsuit seeking to block a Trump administration program to cover certain hemp-derived products through Medicare. That case was dismissed by a federal judge in May, but that decision is being appealed. Read marijuana rescheduling opponents’ full brief in the lawsuit below: The post Pharma Company And Drug Testing Industry Claim Trump’s Rescheduling Move Will ‘Increase Marijuana Abuse’ appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

A new government-funded study is putting quantifiable evidence behind the idea that marijuana use enhances the experience of listening to music. But the new research also suggests that the combination can bolster the therapeutic benefits of cannabis. The study, published in the journal Cannabis and Cannabinoid Research and conducted by researchers at Dalhousie University and other schools in Canada, examined self-reported data from 122 marijuana consumers who completed an exhaustive, 176-question survey. The findings support one of most anecdotally well-established effects of marijuana use: That is, “most participants viewed the combination of cannabis and music favorably, reporting enhanced relaxation, improved mood, and increased feelings of connection,” the paper says. Marijuana use was further linked to “altered responses to imposed music in various settings and a heightened likelihood of using music during routine activities,” the research, which was partially funded by the Natural Sciences and Engineering Research Council of Canada, determined. “Participants reported that combining music and cannabis typically helps reduce fear and anger while enhancing feelings of happiness, liveliness, relaxation, and nostalgia.” Specifically, the study found 93 percent of participants view combining cannabis and music favorably and 74 percent said they use marijuana more than half of the time they’re listening to music. As far as the emotional impact of combining cannabis and music goes, a majority of respondents said it makes them happier (71 percent), more lively (71 percent), more relaxed (70 percent), less fearful (61 percent), less angry (54 percent) and more nostalgic (57 percent). Compared to a control group that took the same survey, marijuana consumers were more likely to incorporate music into daily activities such as bathing, exercising and getting ready for bed. “Cannabis appeared to amplify music’s emotional impact, particularly in mood regulation, evocation of nostalgia, and integration of music into everyday routine,” the researchers said. “Music may act as a meaningful emotional adjunct during cannabis use.” A somewhat more novel discovery from the survey results concerned the therapeutic efficacy of the cannabis-music combination. Participants “frequently reported the use of cannabis as a substitute for pharmaceutical treatments for pain, anxiety, and sleep disorders, with music further amplifying these therapeutic effects,” the study—which looked at use patterns, musical engagement activities, emotional responses and more—found. Among those who use cannabis, significant portions said it serves as a substitute for pharmaceuticals, including sleeping pills (28 percent), anti-anxiety medication (18 percent), antidepressants (16 percent), opioids (12 percent) and non-opioid pain medicine (6 percent). The study authors said “no significant differences were observed in overall music reward experiences with or without cannabis,” however, “highlighting the nuanced and context-dependent nature of these interactions.” “These findings provide novel insights into the potential for cannabis and music to act as complementary tools for emotional well-being, underscoring the need for further research to elucidate the mechanisms underlying their combined effects. This study provides a foundation for future investigations into the therapeutic integration of music as a supportive adjunct to cannabinoid-based interventions targeting emotional and psychological health.” Olivier Valentin, an assistant professor of audiology at Dalhousie University and one of the authors of the study, told Marijuana Moment that “despite countless anecdotal reports, and despite cannabis now being legal and widely used across Canada, science still knows remarkably little about how it shapes the way we hear and appreciate music.” “People often assume cannabis changes music perception itself,” he said. “Our findings suggest something more nuanced: participants didn’t report major changes in how they perceived the music, but they did report that it became more emotionally meaningful. Cannabis seemed to amplify the emotional experience of music rather than the sound itself.” Given the strong interest in putting science behind the shared consumer experience, Canadian researchers at Toronto Metropolitan University published a study in 2024 that “highlights the profound yet idiosyncratic effects of cannabis on auditory experiences among experienced recreational cannabis users.” Whereas that study involved asking participants to reflect on their past experiences being high and listening to music, the team set out on a follow-up project last year that gave them an opportunity to ask consumers about their enjoyment and absorption of music while directly under the influence of marijuana. Speaking to the underlying relationship between music and cannabis, a U.S. government-supported study published this year found that more than a third of popular hip hop and rap music videos referenced marijuana in 2024. Artists like Snoop Dogg and Dr. Dre have helped drive that trend by promoting a “chilled” lifestyle, the researchers said. The post Combining Marijuana And Music Enhances Medical Benefits, Reduces Prescription Drug Use And Boosts Emotions, Government-Funded Study Shows appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net